Search results
Pulmonary function testing (PFT), along with chest imaging, is often the initial testing obtained by the respiratory physician in evaluation of the patient with dyspnea and is often used to monitor response to therapy.
24 paź 2023 · Clinicians have been involved with the disease activity and severity of sarcoidosis through clinical symptoms, radiological imaging, the pulmonary function test (PFT), and blood tests. The PFT plays an important role in the initial workup, diagnosis, and treatment monitoring, as well as follow-up of the disease.
24 paź 2023 · A diffusing capacity for carbon monoxide (DLCO) < 60% as well as a forced vital capacity (FVC) < 70% portends clinically significant pulmonary sarcoidosis pathology and warrants treatment.
24 paź 2023 · The pulmonary function test (PFT) has been widely used in sarcoidosis. It may vary due to the severity, extent, and the presence of complications of the disease. Although the PFT of most sarcoidosis patients is normal, there are still 10–30% of cases who may experience a decrease in the PFT, with a progressive involvement of lungs.
6 cze 2021 · Among the results of lung function tests, forced vital capacity (FVC) is an important parameter for monitoring disease (and response to treatment) in pulmonary sarcoidosis; the diffusing capacity of the lung for carbon monoxide (DLco) and forced expiratory volume in the first second (FEV1) are also important . A Delphi panel agreed that changes ...
Sarcoidosis is a granulomatous disease of unknown cause, occurs worldwide and has a highly variable prevalence. The disease is typically dominant in the lungs, although it can affect virtually any organ and is unpredictable in its clinical course. The severity of pulmonary sarcoidosis ranges from incidentally discovered radiographic ...
The literature on pulmonary function testing in sarcoidosis is critically reviewed. The results indicate that pulmonary function tests are not a reliable means for detecting the presence of parenchymal sarcoidosis, nor do they provide an accurate estimate of the extent of parenchymal disease.
